With much of the world at various levels of lockdown for most of 2020, face to face interaction has been hugely restricted for clinical trials. For many, this has meant either the postponement of studies, or a rapid adoption of decentralized or hybrid trials. At the same time, clinical trials have taken on huge importance in the development of both treatment and a vaccine for COVID-19, moving through phases faster than ever before. In this edition of the Clinical Trials eBook Series, we take an in-depth look at the impact that COVID-19 has had on clinical trials.
Click on the image above or here, to read the interactive report, or jump straight to any of the articles:
- DATA REPORT: The impacts of COVID-19 on clinical trials - Deep dive into the data from a recent Informa Connect Life Sciences study into how those working in clinical trials have been impacted by the pandemic.
- Coronavirus Diaries - Olivia Barnes, Senior Research Nurse at Sherbourne Medical Centre in Leamington Spa, discusses how COVID-19 is impacting the clinical trials she is working on.
- Today’s transformations for COVID-19 are tomorrow’s standards - Never, in the history of healthcare, have so many organizations come together to collaborate that will evolve clinical trials today and for the future.
- WEBINAR: Vaccine Acceptability - Professor Robert Dingwall, Professor of Sociology at Nottingham Trent University discusses what the social sciences have to offer vaccine development.
- INDUSTRY VOICES: Conducting clinical trials during COVID-19 - Three industry insiders offer insights into their experience of the challenges of conducting studies during the pandemic and associated lockdowns.